BR0009465A - Formulação farmacêutica na forma de uma cápsula par administração oral, uso de undecanoato de testosterona, e, método de tratamento compreendendo a administração de undecanoato de testosterona a um homem em necessidade de suplementação de andrógeno - Google Patents
Formulação farmacêutica na forma de uma cápsula par administração oral, uso de undecanoato de testosterona, e, método de tratamento compreendendo a administração de undecanoato de testosterona a um homem em necessidade de suplementação de andrógenoInfo
- Publication number
- BR0009465A BR0009465A BR0009465-0A BR0009465A BR0009465A BR 0009465 A BR0009465 A BR 0009465A BR 0009465 A BR0009465 A BR 0009465A BR 0009465 A BR0009465 A BR 0009465A
- Authority
- BR
- Brazil
- Prior art keywords
- testosterone undecanoate
- administration
- oral administration
- capsule
- man
- Prior art date
Links
- 229960000746 testosterone undecanoate Drugs 0.000 title abstract 6
- UDSFVOAUHKGBEK-CNQKSJKFSA-N testosterone undecanoate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCCCCCCCC)[C@@]1(C)CC2 UDSFVOAUHKGBEK-CNQKSJKFSA-N 0.000 title abstract 6
- 239000003098 androgen Substances 0.000 title abstract 2
- 239000002775 capsule Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000009469 supplementation Effects 0.000 title 1
- 239000007788 liquid Substances 0.000 abstract 3
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 abstract 2
- 239000004359 castor oil Substances 0.000 abstract 2
- 235000019438 castor oil Nutrition 0.000 abstract 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
- 229960003604 testosterone Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Fats And Perfumes (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
Abstract
"FORMULAçãO FARMACêUTICA NA FORMA DE UMA CáPSULA PARA ADMINISTRAçãO ORAL, USO DE UNDECANOATO DE TESTOSTERONA, E, MéTODO DE TRATAMENTO COMPREENDENDO A ADMINISTRAçãO DE UNDECANOATO DE TESTOSTERONA A UM HOMEM EM NECESSIDADE DE SUPLEMENTAçãO DE ANDRóGENO" Divulgada é uma formulação farmacêutica na forma de uma cápsula para administração oral compreendendo undecanoato de testosterona como um ingrediente ativo dissolvido em um veiculo liquido farmaceuticamente aceitável, caracterizado em que o veículo liquido compreende pelo menos 50% em peso de óleo de ricino. A escolha de óleo de rícino como o veiculo liquido, em conjunção com a escolha de undecanoato de testosterona como o andrógeno, produz uma solução que compreende cerca de 200 a 250 mg/ml de TU. Esta é uma nova conquista para qualquer solução oralmente administrável de testosterona. A solução pode também conter um tensoativo lipofílico tal como lauroglicol.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99302581 | 1999-04-01 | ||
| PCT/EP2000/002677 WO2000059512A1 (en) | 1999-04-01 | 2000-03-27 | Formulation comprising testosteron undecanoate and castor oil |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0009465A true BR0009465A (pt) | 2002-01-08 |
Family
ID=8241306
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0009465-0A BR0009465A (pt) | 1999-04-01 | 2000-03-27 | Formulação farmacêutica na forma de uma cápsula par administração oral, uso de undecanoato de testosterona, e, método de tratamento compreendendo a administração de undecanoato de testosterona a um homem em necessidade de suplementação de andrógeno |
Country Status (27)
| Country | Link |
|---|---|
| EP (1) | EP1189620B1 (pt) |
| JP (1) | JP2002541111A (pt) |
| KR (1) | KR100666016B1 (pt) |
| CN (1) | CN1155385C (pt) |
| AT (1) | ATE269708T1 (pt) |
| AU (1) | AU768537B2 (pt) |
| BR (1) | BR0009465A (pt) |
| CA (1) | CA2366856C (pt) |
| CZ (1) | CZ298573B6 (pt) |
| DE (1) | DE60011771T2 (pt) |
| DK (1) | DK1189620T3 (pt) |
| ES (1) | ES2222199T3 (pt) |
| HK (1) | HK1043544A1 (pt) |
| HU (1) | HU229455B1 (pt) |
| ID (1) | ID30481A (pt) |
| IL (2) | IL145524A0 (pt) |
| MX (1) | MXPA01009919A (pt) |
| NO (1) | NO329420B1 (pt) |
| NZ (1) | NZ514290A (pt) |
| PL (1) | PL195163B1 (pt) |
| PT (1) | PT1189620E (pt) |
| RU (1) | RU2246296C2 (pt) |
| SK (1) | SK286071B6 (pt) |
| TR (1) | TR200102769T2 (pt) |
| TW (1) | TWI280124B (pt) |
| WO (1) | WO2000059512A1 (pt) |
| ZA (1) | ZA200107781B (pt) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6652880B1 (en) | 1999-04-01 | 2003-11-25 | R.P. Scherer Technologies, Inc. | Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants |
| GB9907715D0 (en) * | 1999-04-01 | 1999-05-26 | Scherer Corp R P | Pharmaceutical compositions |
| JO2505B1 (en) * | 2003-03-14 | 2009-10-05 | باير شيرنغ فارما اكتنجيسيلشافت | Pharmacy methods and formulations for obtaining acceptable serum testosterone levels |
| DK1530965T3 (da) | 2003-11-11 | 2006-07-17 | Mattern Udo | Kontrolleret frigivelsesleveringssystem til nasal applikation |
| US8784869B2 (en) | 2003-11-11 | 2014-07-22 | Mattern Pharma Ag | Controlled release delivery system for nasal applications and methods of treatment |
| US20060140820A1 (en) | 2004-12-28 | 2006-06-29 | Udo Mattern | Use of a container of an inorganic additive containing plastic material |
| US8492369B2 (en) | 2010-04-12 | 2013-07-23 | Clarus Therapeutics Inc | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
| WO2006113505A2 (en) * | 2005-04-15 | 2006-10-26 | Clarus Therapeutics, Inc. | Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same |
| CA2664427C (en) | 2006-10-04 | 2012-06-05 | M & P Patent Aktiengesellschaft | Controlled release delivery system for nasal application of neurotransmitters |
| GB0818473D0 (en) | 2008-10-08 | 2008-11-12 | Probio Nutraceuticals As | Composition |
| US11304960B2 (en) | 2009-01-08 | 2022-04-19 | Chandrashekar Giliyar | Steroidal compositions |
| CA2795908C (en) * | 2010-04-12 | 2015-10-13 | Clarus Therapeutics, Inc. | Oral testosterone ester formulations and methods of treating testoterone deficiency comprising same |
| GB201006200D0 (en) * | 2010-04-14 | 2010-06-02 | Ayanda As | Composition |
| US9358241B2 (en) | 2010-11-30 | 2016-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US20180153904A1 (en) | 2010-11-30 | 2018-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US20120148675A1 (en) | 2010-12-10 | 2012-06-14 | Basawaraj Chickmath | Testosterone undecanoate compositions |
| BR112013019257B1 (pt) * | 2011-01-26 | 2019-09-03 | Allergan Inc | composição de androgênio para tratar uma condição oftálmica |
| US20130045958A1 (en) | 2011-05-13 | 2013-02-21 | Trimel Pharmaceuticals Corporation | Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder |
| US9757388B2 (en) | 2011-05-13 | 2017-09-12 | Acerus Pharmaceuticals Srl | Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels |
| AR086400A1 (es) | 2011-05-13 | 2013-12-11 | Trimel Pharmaceuticals Corp | Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo |
| US11744838B2 (en) | 2013-03-15 | 2023-09-05 | Acerus Biopharma Inc. | Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event |
| CA2950670A1 (en) | 2014-06-17 | 2015-12-23 | Merck Sharp & Dohme B.V. | Stable formulations of testosterone undecanoate |
| CA2948225C (en) * | 2014-06-19 | 2022-05-31 | Solural Pharma ApS | Solid oral dosage form of lipophilic compounds |
| WO2016033556A1 (en) | 2014-08-28 | 2016-03-03 | Lipocine Inc. | BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS |
| US20170246187A1 (en) | 2014-08-28 | 2017-08-31 | Lipocine Inc. | (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE |
| CN106999558A (zh) * | 2014-08-29 | 2017-08-01 | 来普卡公司 | (17‑β)‑3‑氧雄甾‑4‑烯‑17‑基十一酸酯组合物及其制备方法和用途 |
| CA3078723A1 (en) | 2016-11-28 | 2018-05-31 | Nachiappan Chidambaram | Oral testosterone undecanoate therapy |
| US20200155570A1 (en) * | 2018-07-20 | 2020-05-21 | Lipocine Inc. | Liver disease |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1102095A (zh) * | 1993-10-30 | 1995-05-03 | 浙江医科大学 | 长效雄激素类制剂——十一酸睾丸注射液 |
| GB9608719D0 (en) * | 1996-04-26 | 1996-07-03 | Scherer Ltd R P | Pharmaceutical compositions |
| SE9700642D0 (sv) * | 1997-02-24 | 1997-02-24 | Kronvall Stefan Med Ab | Medel och sätt för förebyggande och behandling av det metabola syndromet |
-
2000
- 2000-03-27 BR BR0009465-0A patent/BR0009465A/pt not_active Application Discontinuation
- 2000-03-27 AT AT00920588T patent/ATE269708T1/de active
- 2000-03-27 CA CA002366856A patent/CA2366856C/en not_active Expired - Lifetime
- 2000-03-27 PL PL00351259A patent/PL195163B1/pl unknown
- 2000-03-27 RU RU2001129362/15A patent/RU2246296C2/ru active
- 2000-03-27 EP EP00920588A patent/EP1189620B1/en not_active Expired - Lifetime
- 2000-03-27 ES ES00920588T patent/ES2222199T3/es not_active Expired - Lifetime
- 2000-03-27 PT PT00920588T patent/PT1189620E/pt unknown
- 2000-03-27 DK DK00920588T patent/DK1189620T3/da active
- 2000-03-27 ID IDW00200102082A patent/ID30481A/id unknown
- 2000-03-27 WO PCT/EP2000/002677 patent/WO2000059512A1/en active IP Right Grant
- 2000-03-27 CN CNB008059381A patent/CN1155385C/zh not_active Expired - Lifetime
- 2000-03-27 IL IL14552400A patent/IL145524A0/xx active IP Right Grant
- 2000-03-27 AU AU41111/00A patent/AU768537B2/en not_active Expired
- 2000-03-27 MX MXPA01009919A patent/MXPA01009919A/es active IP Right Grant
- 2000-03-27 CZ CZ20013507A patent/CZ298573B6/cs not_active IP Right Cessation
- 2000-03-27 HU HU0200453A patent/HU229455B1/hu unknown
- 2000-03-27 KR KR1020017012498A patent/KR100666016B1/ko active IP Right Grant
- 2000-03-27 JP JP2000609075A patent/JP2002541111A/ja not_active Withdrawn
- 2000-03-27 SK SK1372-2001A patent/SK286071B6/sk not_active IP Right Cessation
- 2000-03-27 NZ NZ514290A patent/NZ514290A/en not_active IP Right Cessation
- 2000-03-27 TR TR2001/02769T patent/TR200102769T2/xx unknown
- 2000-03-27 DE DE60011771T patent/DE60011771T2/de not_active Expired - Lifetime
- 2000-05-11 TW TW089109036A patent/TWI280124B/zh not_active IP Right Cessation
-
2001
- 2001-09-20 ZA ZA200107781A patent/ZA200107781B/en unknown
- 2001-09-20 IL IL145524A patent/IL145524A/en not_active IP Right Cessation
- 2001-09-28 NO NO20014718A patent/NO329420B1/no not_active IP Right Cessation
-
2002
- 2002-07-17 HK HK02105288A patent/HK1043544A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0009465A (pt) | Formulação farmacêutica na forma de uma cápsula par administração oral, uso de undecanoato de testosterona, e, método de tratamento compreendendo a administração de undecanoato de testosterona a um homem em necessidade de suplementação de andrógeno | |
| RU2001129362A (ru) | Композиция, включающая ундеканоат тестостерона и касторовое масло | |
| ES2602450T3 (es) | Composición farmacéutica para uso dérmico para el tratamiento de la psoriasis que comprende calcipotril y betametasona | |
| DK1173153T3 (da) | Orale farmaceutiske præparater, som indeholder langkædede triglycerider og lipofile overfladeaktive midler | |
| ES2188782T3 (es) | Formulaciones farmaceuticas que contienen darifenacina. | |
| JP2002539166A5 (pt) | ||
| BR0314761A (pt) | Composto de adenina e seu uso | |
| SI9200403B (en) | New combination of a bronchodilator and a steroidal antiinflammatory drug for treatment of respiratory disorders as well as its use and preparation thereof | |
| CO5271759A1 (es) | Formulacion en solucion que contiene una mezcla de disolventes | |
| PA8542701A1 (es) | Composición parenteral reconstituible | |
| CO4910145A1 (es) | Uso | |
| JP2023061951A (ja) | 皮膚障害の処置 | |
| IT1263840B (it) | Formulazioni orali di ubidecarenone in forma di capsule | |
| ES2054690T3 (es) | Uso farmaceutico de extractos de gramineas. | |
| NZ503551A (en) | PDE4 inhibitors for the treatment of inflammatory skin diseases | |
| ES2238985T3 (es) | Composiciones para el tratamiento de enfermedades de la piel. | |
| AR035946A1 (es) | Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos | |
| NO950134L (no) | Formuleringer for oralt administrerte farmasöytiske midler | |
| JP2010529175A (ja) | マラセチア属酵母に対して抗真菌活性を有するテルペン | |
| US20080119546A1 (en) | Treatment of hyperproliferative conditions of body surfaces | |
| AR023235A1 (es) | Formulaciones de androgenos | |
| JP2003081812A (ja) | エアゾール製剤 | |
| US5556871A (en) | Method for treating epithelial precancerous lesions with topical inidazoles | |
| US20230089681A1 (en) | Use of a combination of sulficant compounds with a liquid carrier as a self emulsifying drug delivery system | |
| AR002716A1 (es) | Uso farmacologico de ciertos derivados de cistina para la preparacion de un medicamento |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) DA LPI |
|
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |